BCTX Stock — BriaCell Therapeutics Corp. Common Shares: Cash, EV, Pipeline

Share price

$4.21

Market cap

$36.6M

Cash

$26.7M

Enterprise value

$9.9M

Balance sheet

Cash	$26.7M
Debt	$0.0M
Net cash	$26.7M
Enterprise value	$9.9M
Basic shares	7.3M shares
Fully diluted shares	10.4M shares
Fully diluted market cap	$43.8M
Cash per share	$3.66

Cash figures as of 2026-06-02. Database snapshot: 2026-09-21.

Price history

Loading BCTX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23	SV-BR-1-GM	Phase 3	Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Bria-IMT

Phase 3 · Active Modality: allogeneic whole cell-based cancer vaccine

Indications

Metastatic breast cancer (Phase 3)

Catalysts

— 1H 2026

Status note Pivotal Phase 3 (NCT06072612) of Bria-IMT + retifanlimab (anti-PD-1, manufactured by Incyte) in advanced metastatic breast cancer; FDA Fast Track; enrollment on track per Dec 2025 update (230+ screened, 160+ enrolled).

Bria-OTS

Phase 2 · Active Modality: personalized off-the-shelf immunotherapy

Aliases Bria-BRES

Indications

Metastatic breast cancer (Phase 2)

Status note Phase 1/2 study ongoing (NCT06471673).

Bria-OTS+

Stage not disclosed · Active Modality: personalized off-the-shelf immunotherapy

Aliases Bria-BRES+

Indications

Advanced metastatic breast cancer (Stage not disclosed)

Status note Open IND for clinical evaluation in advanced metastatic breast cancer; first of the enhanced Bria-OTS+ immunotherapies. No trial start stated.

Bria-PROS+

Stage not disclosed · Active Modality: personalized off-the-shelf immunotherapy

Indications

Prostate cancer (Stage not disclosed)

Status note Cell line manufacturing complete for prostate cancer; no clinical study stated in filing.

Per-asset detail extracted from the 10-Q filed 2026-06-09. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SV-BR-1-GM
Lead indication	Breast Cancer
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06072612	Phase 3	Recruiting	Sponsor	BriaCell Therapeutics Corporation	—	Breast Cancer; Metastatic Breast Cancer; Breast Neoplasm	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for BriaCell Therapeutics Corporation on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

BCTX — BriaCell Therapeutics Corp. Common Shares

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials